DOCSLIB.ORG

Ed 260 938 Author Institution Report No Available From

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ed 260 938 Author Institution Report No Available From DOCUMENT RESUME ED 260 938 SE 045 978 AUTHOR Grabowski, John, Ed. TITLE Cocaine: Pharmacology, Effects, and Treatment of Abuse. National Institute on Drug Abuse Research Monograph 50. INSTITUTION National Inst. on Drug Abuse (DHHS/PHS), Rockville, Md. REPORT NO DHHS-ADM-84-1326 PUB DATE 84 NOTE 143p. AVAILABLE FROMSuperintendent of Documents, U.S. Government Printing Office, Washington, DC 20402. PUB TYPE Collected Works - General (020) EDRS PRICE MF01/PC06 Plus Postage. DESCRIPTORS *Drug Abuse; Drug Addiction; Drug Education; *Drug Rehabilitation; *Drug Use; *Neurology; *Pharmacology; Physiology; Public Health IDENTIFIERS *Cocaine ABSTRACT This monograph consists of eight papers which refer in one way or another to the pharmacology of cocaine. The papers are: (1) Cocaine 1984: Introduction and Overview" (John Grabowski); (2) "Cocaine: A Growing Public Health Problem" (Edgar H. Adams and Jack Durell); (3) "Neural Mechanisms of the Reinforcing Action of Cocaine" (Roy A. Wise);(4) "The Pharmacology of Cocaine" (Reese T. Jones); (5) "Assessment of the Dependence Potential of Cocaine in Animals" (Chris E. Johanson);(6) "The Behavioral Pharmacology of Cocaine in Humans" (Marian W. Fischman); (7) "Changing Patterns of Cocaine Use: Longitudinal Observations, Consequences, and Treatment" (Ronald K. Siegel); and (8) "Cocaine Abuse: A Review of Current and Experimental Treatments" (Herbert D. Kleber and Frank H. Gawin). References, some of them extensive, are included for each paper. A list of National Institute on Drug Abuse (NIDA) research monographs is included. (JN) *********************************************************************** * Reproductions supplied by EDRS are the best that can be made * * from the original document. * *********************************************************************** National Institute on Drug Abuse %No t14 SCOPE OF INTEREST NOTICE The ERIC Fealty has assigned this document for proc ossing up MONOGRAPH SERIESto CD In our judgment, the document rs also of interest to the Clear rnghouses noted to the right Indexing should reflect their special points 01 vied/ w U S OEPARIMENT OF EDUCATION NATIONAL INSTITUTE OF EDUCtil ION I Our AT IONA!Elf SOUR( E5 INFORM h I ION E Efil 44. 444,44444,44r ,r44. IOen r01, the I. rttr.,1rrhls, ,1 Cocaine: tort00,`JAC 11)1,10 ,11, 11i, 111,1, ,1 rtlr,14.0.44 II,lot, 4.4.,41 4r 4, Pharmacology, r4,,E,414,4 ,14,14,,r,1441E, 44.1 NIE Effects, and Treatment of Abuse BES[ COP(iivAILABLE U S DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Servo Alcohol. 01110 Abuse, and Mental Health Adennistration 2 Cocaine: Pharmacology, Effects, and Treatment of Abuse Editor: John Grabowski, Ph.D. Division of Clinical Research National Institute on Drug Abuse N I DA Research Monograph 50 1984 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Aoministration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, V S Government Printing Office Washington, D.C. 20402 3 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art confer- ences, integrative research reviews and significant original research Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. University of Connecticut School of Medicine Farmington. Connecticut Reese T. Jones, M.D. Langley Paler Neuropsychiatric Institute University of California San Francisco. California Jack Mendelson, MD Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Now lis, Ph.D. Rochester. New York Lee Robins, Ph.D. Washington University School of Medicine St Louis. Missoun NIDA Research Monograph Series William Po llin, M.D. DIRECTOR, NIDA Jack Durell, M.D. ASSOCIATE DIRECTOR, OFFICE OF SCIENCE, NiDA EDITOR-IN-CHIEF Eleanor W.1Waldrop MANAGING EDITOR Park lawn Building 5600 Fishers Lane. Rockville Maryland 20857 4 Dr. John Grabowski, editor of this monograph, was on the staff of the Behavioral Pharmacology Branch, Division of Clinical Research, NIDA. He is now affiliated with the Department of Psychiatry, School of Medicine, Louisiana State University, Shreveport, Louisiana 71130. COPYRIGHT STATUS All material in this volume except quoted passages from copyrighted sources is inthe public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part ofthe U.S. Department of Health and Human Services. Library of Congress catalog card number 84-601074 DRS publication number (ADM)84-1326 Printed 1984 NIDA Research Monographs are indexed in the Index Medicus.They are selectively included in the coverage of American Statistics Index, BioSciences Information Service, Chemical AbstaT7 trurrent Contents, Psychological Abstracts, and Psychopharmacology AIStr acts. iv 5 Contents Foreword William Pollin vii Cocaine 1984: Introduction and Overview John Grabowski 1 Cocaine: A Growing Public Health Problem Edgar H. Adams and Jack Durell 9 Neural Mechanisms of the Reinforcing Action of Cocaine Roy A. Wise 15 The Pharmacology of Cocaine Reese T. Jones 34 Assessment of the Dependence Potential of Cocaine in Animals Chris E. 'chanson 54 The Behavioral Pharmacology of Cocaine in Humans Marian W. Fischman 72 Changing Patterns of Cocaine Use: Longitudinal Observations, Consequences, and Treatment Ronald K. Siegel 92 Cocaine Abuse: A Review of Current and Experimental Treatments Herbert D. Kleber and Frank H. Gawin 111 List of NIDA Research Monographs 130 V Foreword Cocaine is currently the drug of greatest national concern, from a public health point of view, and of particularly high interest from the research and scientific point of view. The public health concern derives from the following sources: It has shown the highest continuing rate of increase in DAWN mentions (emergency room visits), cverdose deaths, and serious clinical problems, despite a leveling of national prevalence since 1980. Animal studies show it to be one of the most potent reinforcers available. It is the one drug most easily and universally accepted in animal self-administration studies without prior induction training, and is widely used to shape animal behavior for the self-administration of other reinforcing drugs. It has one of the highest reinforcing potentials as meacured by breaking point studies, and is the drug which animals, with unlimited access, are most likely to select repeatedly in preference to food and water to the point of death.These preclinical observations and related clinical data lead to the conclusion that the prospect of substantial increases in available supply and decreases in price constitutes a major and growing public health danger. We are still uncertain as to whether the leveling off in overall national prevalence, which as shown by our two major national surveys occurred for cocaine between 1979 and 1982, has continued since then. If so, the increase in medical complications, addiction, and clinical problems described above would represent a higher percentage of a constant total pool of users running into serious problems. This interpretation is consistent with studies showing that an average of 4 to 5 years elapses between first use of cocaine and the need for treatment, and other studies showing that the best predictor of cocaine use is heavy, early marijuana use. The current upsurge in public health related cocaine problems would then be the predictable second stage of the peak of marijuana use which we saw in this country in the late 1970s. An alternative possibility is that greatly increased availability of this most reinforcing illicit drug has broken through powerful cultural and demographic barriers and begun to lead to a substantial increase in the number of users and/or intensified patterns of use. Evidence for this latter alternative may only become evident in future national surveys. vii In any event, while we await further clarificationof the exact nature of current trends in cocaine use, there isan urgent need for a rapid increase in information on mechanisms of brain action, treatment methods, health consequences, and preventionstrategies. This monograph makes an important contribution towards planning future research by reviewing our knowledge base. William Pollin, M.D. Director National Institute on Drug Abuse viii 8 Cocaine 1984: Introduction and Overview John Grabowski INTRODUCTION Diverse aspectsof cocaine pharmacology, use, and effects have been discussed at length in both the lay press and the scientific literature. Researchinvolving cocaine has a long, interestinghistory which has been described at intervals, and this volume provides a current review of present knowledge concerning the drug. Dramatic increases in use in the past decade, increasing evidence of untoward consequences of use, and resultant public health concerns also set the stage for a timelyand thorough review of scientific and clinical issues concerning cocaine.
Load more

Recommended publications
  • Slang Terms and Code Words: a Reference for Law Enforcement
    UNCLASSIFIED Slang Terms and Code Words: A Reference for Law DEA Enforcement Personnel Intelligence DEA-HOU-DIR-022-18 July 2018 ReportBrief 1 UNCLASSIFIED UNCLASSIFIED DEA Intelligence Report Executive Summary This Drug Enforcement Administration (DEA) Intelligence Report contains new and updated information on slang terms and code words from a variety of law enforcement and open sources, and serves as an updated version to the product entitled “Drug Slang Code Words” published by the DEA in May 2017. It is designed as a ready reference for law enforcement personnel who are confronted with hundreds of slang terms and code words used to identify a wide variety of controlled substances, designer drugs, synthetic compounds, measurements, locations, weapons, and other miscellaneous terms relevant to the drug trade. Although every effort was made to ensure the accuracy and completeness of the information presented, due to the dynamics of the ever-changing drug scene, subsequent additions, deletions, and corrections are inevitable. Future addendums and updates to this report will attempt to capture changed terminology to the furthest extent possible. This compendium of slang terms and code words is alphabetically ordered, with new additions presented in italic text, and identifies drugs and drug categories in English and foreign language derivations. Drug Slang Terms and Code Wordsa Acetaminophen and Oxycodone Combination (Percocet®) 512s; Bananas; Blue; Blue Dynamite; Blueberries; Buttons; Ercs; Greenies; Hillbilly Heroin; Kickers; M-30s;
    [Show full text]
  • Smokable Cocaine Markets in Latin America and the Caribbean a Call for a Sustainable Policy Response
    Smokable cocaine markets in Latin America and the Caribbean A call for a sustainable policy response ideas into movement AUTHORS: Ernesto Cortés and Pien Metaal EDITOR: Anthony Henman DESIGN: Guido Jelsma - www.guidojelsma.nl COVER PHOTO: Man smoking crack pipe Colombia, L. Niño. ACKNOWLEDGEMENTS: This publication was made possible through the financial support of the Open Society Foundation (OSF) and the Global Partnership on Drug Policies and Development (GPDPD). GPDPD is a project implemented by the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH on behalf of the Federal Ministry for Economic Cooperation and Development (BMZ) and under the political patronage of the Federal Government’s Drug Commissioner. The contents of this report are the sole responsibility of TNI and can under no circumstances be regarded as reflecting the position of the donors. PUBLICATION DETAILS: Contents of the report may be quoted or reproduced for non-commercial purposes, provided that the source of information is properly cited. TRANSNATIONAL INSTITUTE (TNI) De Wittenstraat 25, 1052 AK Amsterdam, The Netherlands Tel: +31-20-6626608, Fax: +31-20-6757176 E-mail: [email protected] www.tni.org/drugs @DrugLawReform Drugsanddemocracy Amsterdam, December 2019 2 | Smokable cocaine markets in Latin America and the Caribbean transnationalinstitute Contents Introduction 4 Methodological approach 6 The Substance(s) 8 Smokable cocaine in Cochabamba (Bolivia) in the early 1990s 9 Users 14 Impact on health 17 The Market 21 Harm Reduction experiences 25 Conclusions and Discussion 28 Policy Recommendations 29 Good Practices: examples from Brazil 30 Bibiography and references 32 International smokable cocaines working group 33 Endnotes 34 transnationalinstitute Smokable cocaine markets in Latin America and the Caribbean | 3 Introduction regions.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Drugs and Development: the Great Disconnect
    ISSN 2054-2046 Drugs and Development: The Great Disconnect Julia Buxton Policy Report 2 | January 2015 Drugs and Development: The Great Disconnect Julia Buxton∗ Policy Report 2 | January 2015 Key Points • The 2016 United Nations General Assembly Special Session on the World Drug Problem (UNGASS) will see a strong lobby in support of development oriented responses to the problem of drug supply, including from the United Nations Office on Drugs and Crime (UNODC). • The promotion of Alternative Development (AD) programmes that provide legal, non-drug related economic opportunities for drug crop cultivators reflects the limited success of enforcement responses, greater awareness of the development dimensions of cultivation activities and the importance of drugs and development agencies working co-operatively in drug environments. • Evidence from thirty years of AD programming demonstrates limited success in supply reduction and that poorly monitored and weakly evaluated programmes cause more harm than good; there has been little uptake of best practice approaches, cultivators rarely benefit from AD programmes, the concept of AD is contested and there is no shared understanding of ‘development’. • AD was popularised in the 1990s when development discourse emphasised participatory approaches and human wellbeing. This is distinct from the development approaches of the 2000s, which have been ‘securitised’ in the aftermath of the Global War on Terror and which re-legitimise military participation in AD. • UNGASS 2016 provides an opportunity for critical scrutiny of AD and the constraints imposed by the 1961 Single Convention on Narcotic Drugs on innovative, rights based and nationally owned supply responses. Cultivation is a development not a crime and security issue.
    [Show full text]
  • Misuse of Drugs Regulations 2017 2 [173]
    STATUTORY INSTRUMENTS. S.I. No. 173 of 2017 ———————— MISUSE OF DRUGS REGULATIONS 2017 2 [173] S.I. No. 173 of 2017 MISUSE OF DRUGS REGULATIONS 2017 ARRANGEMENT OF REGULATIONS PART 1 Preliminary and General 1. Citation and commencement. 2. Interpretation. PART 2 Issuing of Prescriptions by Registered Nurses and Registered Midwives 3. Provisions applicable to practitioners who are registered nurses or regis- tered midwives. 4. Person may refuse to supply drug if reasonable cause to believe conditions referred to in regulation 3 have not been satisfied. PART 3 Production, Supply, Importation and Exportation of Controlled Drugs 5. General prohibition. 6. Licences. 7. Administration. 8. Exemption for practitioners, pharmacists, etc. 9. Supply. PART 4 Possession of Controlled Drugs 10. General exemptions. 11. Exemption to possess butan-1,4-diol or dihydrofuran-2(3H)-one. 12. Exemption for midwives in respect of pentazocine and pethidine. 13. General authorities. PART 5 Documentation and Record-Keeping 14. Documents to be obtained by a supplier. [173] 3 15. Form of prescriptions. 16. Supply on prescription. 17. Marking of containers. 18. Documents required for export of controlled drugs. 19. Keeping of registers for drugs in Schedules 1 and 2. 20. Record-keeping in particular cases for drugs in Schedule 2. 21. Keeping of records for drugs in Schedules 3 and 4. 22. Preservation of registers, etc. 23. Preservation of records for drugs in Schedules 3, Part 1 of Schedule 4, and Schedule 5. 24. Furnishing of information with respect to controlled drugs. PART 6 Miscellaneous 25. Destruction of certain drugs. 26. Disposal of certain drugs on cessation of business.
    [Show full text]
  • Booklet 4 Stimulants Preface
    4 STIMULANTS 4 STIMULANTS 2019 2019 © United Nations, June 2019. All rights reserved worldwide. ISBN: 978-92-1-148314-7 eISBN: 978-92-1-004174-4 United Nations publication, Sales No. E.19.XI.8 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] Website: www.unodc.org/wdr2019 PREFACE The findings of this year’s World Drug Report fill in same time clamping down on organized crime and and further complicate the global picture of drug trafficking.
    [Show full text]
  • Production and Supply of Drugs, Pharmaceuticals, and Chemical Precursors
    THE DRUG PROBLEM IN THE AMERICAS: STUDIES PRODUCTION AND SUPPLY OF DRUGS, PHARMACEUTICAL, AND CHEMICAL PRECURSORS Organization of American States 1 2 The Drug Problem in the Americas: Studies TABLE OF CONTENTS Findings ..................................................................................................................... 5 PART 1 COCAINE AND HEROIN ........................................................................................ 7 COCAINE PRODUCTION AND DISTRIBUTION.................................................................. 7 Coca Cultivation ...................................................................................................... 8 Cocaine Manufacturing ........................................................................................... 11 Cocaine Flows ....................................................................................................... 12 Transport Methods................................................................................................. 15 HEROIN PRODUCTION AND DISTRIBUTION .................................................................. 15 POLICIES TO CONFRONT COCAINE AND HEROIN PRODUCTION AND TRAFFICKING ............ 17 Illicit Crop Reduction .................................................................................................. 17 Impact of Crop Reduction Policies ................................................................................ 18 Interdiction and Attacks on Organizations ....................................................................
    [Show full text]
  • Cocaine: Pharmacology, Effects, and Treatment of Abuse
    Cocaine: Pharmacology, Effects, and Treatment of Abuse U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Cocaine: Pharmacology, Effects, and Treatment of Abuse Editor: John Grabowski, Ph.D. Division of Clinical Research National Institute on Drug Abuse NIDA Research Monograph 50 1984 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY, COHEN M.D. Temple University School of Medicine LosAngeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic Institute National Federation of Parents for Troy, New York Drug Free Youth RICHARD BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTMAN Langley Porter Neuropsychiatric Institute San Francisco, California Alcohol and Drug Problems Association of North America Washington, D.C. DENISE KANDEL, Ph.D. GILBERT J. BOVTIN, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • Newer Unregulated Drugs Look-Up Table
    Newer Unregulated Drugs Look-up Table List Name Chemical Name/AKA Type of drug Notes Stimulant Regulation under MDA (Sch. 1 or TCDO) Stimulant/Hallucinogen Regulation under MDA (Sch. 2-5) Hallucinogen Regulated by PSA Depressant Exempt Cannabinoid Uncertain/requires clarification 1P-LSD 1-propionyl-lysergic acid diethylamide Hallucinogen An LSD analogue that side-stepped MDA and was on sale as an NPS; now covered by the PSA. 2-AI 2-Aminoindane Stimulant, amphetamine analogue Reported in the UK in 2011 by the Forensic Early 2-MAI N-methyl-2-Aminoindane Warning System (FEWS). Had been on sale via number MMAI of online stores; covered by PSA. 2-MeO-ketamine Methoxyketamine Related to methoxetamine so a relative Believed to have been made a CD at the same time as Methoxieticyclidine of ketamine – i.e. a dissassociative Methoxetamine anaesthetic hallucinogen 2C-B-BZP (1-(4-bromo-2,5- Piperazine family; stimulant Class B dimethoxybenzyl)piperazine) 2-DPMP Desoxypipadrol stimulant Strong and long acting stimulant; reported duration of 2-diphenylmethylpiperidine effect 24-28hrs or more and effective at very low doses. Had been on sale in the UK and cropped up in branded “Ivory Wave” and in other compounds. Linked to fatalities. Class B, Sch1. 2-NE1 APICA Synthetic cannabinoid receptor agonist 3rd generation SCRA. Covered by PSA SDB-001 N-(1-adamantyl)-1-pentyl-1H-indole-3- carboxamide 3-FPM Phenzacaine Stimulant, euphoriants Sibling of the controlled drug Phenmetrazine. Emerged PAL-593 2015. Covered by PSA 2-(3-fluorophenyl)-3-methylmorpholine 3-hydroxyphenazepam Benzo, GABA-nergic PSA 3-MeO-PCE (3-methoxyeticyclidine) Related to methoxetamine so a relative Probably regulated under the same clause that made of ketamine – i.e.
    [Show full text]
  • 1951 Cocainas Fumables Pascale ENG
    INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D Secretariat for Multidimensional Security FIFTY-FIRST REGULAR SESSION OEA/Ser.L/XIV.2.51 May 9 -11, 2012 CICAD/doc.1951/12 Washington, D.C. 8 May 2012 Original: Español SMOKEABLE COCAINE IN SOUTH AMERICA DR. ANTONIO PASCALE PRIETO REDLA, URUGUAY Smokeable Cocaine in South America Dr. Antonio Pascale Prieto M.D., Toxicologist –REDLA Montevideo, Uruguay LI CICAD Regular Session CICAD - OAS, Washington DC . USA May 9-11, 2012 Presentation •Smokeable Cocaine Substances •The Epidemiology of Cocaine Base Paste (CBP) consumption •Profile of the CBP user •CBP: toxicology –health impact -Composition -Toxicity -Addictive Potential -Clinical Aspects -Chronic complications • Therapeutic Approach SMOKEABLE COCAINE Coca Leaf Kerosene Alkaline Substances Gasoline Sulphuric Acid COCAINE BASE PASTE BASUCO (Colombia) Hydrochloric Acid Acetone Ethanol COCAINE HYDROCHLORIDE Sodium Bicarbonate Sodium Bicarbonate Ammonia Ammonia Ether water Temp. 800° C Temp. 98° C FREE BASE CRACK Modificado de Castaño, 2000 Epidemiology of CBP consumption Surveys indicate low prevalence of consumption… …however impact is high. (demand for treatment, consultations related to acute and chronic effects) Consumption in the General Population Report on Drug Use in the Americas. OID. CICAD. OEA (2011) IV National Household Survey (2006) –Consumption of CBP in Uruguay 0,8 0,7 0,6 0,5 0.8 Prev. de vida 0,4 Ultimos 12 meses 0,3 Ultimos 30 dias 0,2 0.3 0,1 0.1 0 % -Signs of Dependency in 57 % of consumers -Three out of four CBP users are males -Average age of first use: 20 years. -History of inhalant abuse (60 %) 8% in highly vulnerable, peripheral areas in Montevideo Source: Uruguayan Observatory on Drugs.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub
    US 20110263526A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub. Date: Oct. 27, 2011 (54) NITRICOXIDE RELEASING PRODRUGS OF CD7C 69/96 (2006.01) THERAPEUTICAGENTS C07C 319/22 (2006.01) CD7C 68/02 (2006.01) (75) Inventor: Apparao SATYAM, Mumbai (IN) A6IP 29/00 (2006.01) A6IP 9/00 (2006.01) (73) Assignee: PIRAMAL LIFE SCIENCES A6IP37/08 (2006.01) LIMITED, Mumbai (IN) A6IP35/00 (2006.01) A6IP 25/24 2006.O1 (21) Appl. No.: 13/092.245 A6IP 25/08 308: A6IP3L/04 2006.O1 (22) Filed: Apr. 22, 2011 A6IP3L/2 308: Related U.S. Application Data 39t. O 308: (60) Provisional application No. 61/327,175, filed on Apr. A6IP3/10 (2006.01) 23, 2010. A6IPL/04 (2006.01) A6IP39/06 (2006.01) Publication Classification A6IP3/02 (2006.01) (51) Int. Cl. A6IP 9/06 (2006.01) A 6LX 3L/7072 (2006.01) 39t. W 308: A6 IK3I/58 (2006.01) A6IP II/08 (2006.015 A6 IK3I/55 (2006.01) A63/62 (2006.015 A6 IK 3/495 (2006.01) A6 IK 3/4439 (2006.01) (52) U.S. Cl. ........... 514/50: 514/166; 514/172: 514/217; A6 IK 3L/455 (2006.01) 514/255.04: 514/338; 514/356; 514/412; A6 IK 3/403 (2006.01) 514/420; 514/423: 514/510,536/28.53:540/67; A6 IK 3/404 (2006.01) 540/591; 544/396; 546/273.7: 546/318: 548/452: A6 IK 3/40 (2006.01) 548/500: 548/537; 549/464; 558/275 A6 IK3I/265 (2006.01) C7H 9/06 (2006.01) (57) ABSTRACT CO7I 71/00 (2006.01) CO7D 22.3/26 (2006.01) The present invention relates to nitric oxide releasing pro C07D 295/14 (2006.01) drugs of known drugs or therapeutic agents which are repre CO7D 40/12 (2006.01) sented herein as compounds of formula (I) wherein the drugs CO7D 213/80 (2006.01) or therapeutic agents contain one or more functional groups C07D 209/52 (2006.01) independently selected from a carboxylic acid, an amino, a CO7D 209/26 (2006.01) hydroxyl and a sulfhydryl group.
    [Show full text]
  • Freebase Cocaine in Mainland France: Recent Trends
    Updates on current research Freebase cocaine in mainland France: recent trends Michel At the end of the 2000s, the OFDT’s Gandilhon, TREND (Emerging Trends and New Drugs) scheme, which focuses on fol- Analysis of crack cocaine and freebase cocaine lowing intense drug-using populations, use and markets from a specific investigation Agnès within the 2011-2012 TREND scheme. Cadet-Taïrou, revealed trends on access to freebase co- caine - including crack cocaine - and its use. These trends were practically undetec- Emmanuel 1 Lahaie table in general population surveys . There was an observed emergence in several pro- vincial cities of micromarkets for freebase cocaine, which was previously produced on a small scale for individual consumption. At the same time, in Paris, the crack market underwent changes in terms of both sup- ply and demand. Given the highly addictive nature of freebase cocaine, the increased accessibility of this drug led TREND to in the United States since the mid-70s; the focus on examining these market changes. crack use phenomenon travelled to main- To confirm and explain the observed phe- land France through the French overseas nomena, in 2011 and 2012, six out of the departments (Martinique, French Guiana, seven TREND sites (Bordeaux, Marseille, Guadeloupe) [1]. Until the early 2000s, use Metz, Paris, Rennes, Toulouse) conduc- of this form of cocaine remained fairly stable ted a specific investigation. This issue of in terms of user profile (the vast majority of Tendances presents the key results. These users were very marginal) and geographic results, along with the data of the SINTES location (use mainly took place in districts (National Detection System of Drugs and in the north of Paris).
    [Show full text]